Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

have evaluated use of blood neurofilament and other biomarkers as prognostic biomarkers, meaning a biomarker that predicts disease severity and progression, or as a susceptibility risk biomarker ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...